Savara Sees Unusually Large Options Volume (NASDAQ:SVRA)

Savara Inc. (NASDAQ:SVRA) saw some unusual options trading on Friday. Stock investors purchased 2,182 call options on the stock. This is an increase of approximately 290% compared to the typical daily volume of 560 call options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nan Fung Trinity HK Ltd. increased its stake in Savara by 1,088.3% during the third quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after acquiring an additional 1,687,310 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Savara during the third quarter valued at approximately $54,000. Profund Advisors LLC lifted its stake in shares of Savara by 7.3% in the 3rd quarter. Profund Advisors LLC now owns 49,741 shares of the company’s stock valued at $257,000 after purchasing an additional 3,370 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Savara by 14.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 37,488 shares of the company’s stock valued at $190,000 after purchasing an additional 4,874 shares during the last quarter. Finally, Moody Aldrich Partners LLC boosted its holdings in shares of Savara by 4.2% in the 3rd quarter. Moody Aldrich Partners LLC now owns 502,932 shares of the company’s stock worth $2,595,000 after purchasing an additional 20,139 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

SVRA traded up $0.04 during trading hours on Friday, hitting $4.76. The company’s stock had a trading volume of 564,646 shares, compared to its average volume of 1,803,927. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -7.79 and a beta of 0.32. The business’s 50-day moving average price is $4.95 and its 200-day moving average price is $5.34. The company has a current ratio of 8.55, a quick ratio of 10.13 and a debt-to-equity ratio of 0.28. Savara has a 12 month low of $4.13 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. Sell-side analysts expect that Savara will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on SVRA shares. Citigroup restated a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on shares of Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective on the stock. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Savara has an average rating of “Moderate Buy” and a consensus price target of $10.29.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.